Foralumab Shows Imaging Signal in Progressive MS

Company Tiziana Life Sciences Event Type Phase 2a topline (INFORM-MS) Modality Intranasal fully human anti-CD3 antibody Asset Foralumab Target CD3 Disease Area Non-active secondary progressive multiple sclerosis Summary Tiziana reported November 2 topline results from randomized, double-blind, placebo-controlled Phase 2a INFORM-MS in non-active secondary progressive…